FDA backed unapproved peptides but raised purity red flags

An FDA advisory panel recently voted to support continued access to certain unapproved peptides, while also flagging concerns about manufacturing consistency, purity, and potency. Advisory panels don't set policy on their own -- their votes give the FDA expert guidance that can shape future decisions and rulemaking.

The word "unapproved" needs some context here. It means these peptides haven't completed the full FDA drug-approval process, which requires clinical trials demonstrating safety and efficacy for a specific medical indication. That process can take a decade and hundreds of millions of dollars per compound. Many peptides used in research have been studied in laboratories for years without going through that pipeline, because the goal is basic science, not a commercial drug application.

What the Safety Concerns Actually Are

The panel flagged manufacturing quality as the core issue -- specifically how peptides are produced outside GMP (Good Manufacturing Practice) facilities. GMP is the FDA's production standard covering raw material testing, cleanroom conditions, and batch-record documentation. Without it, three problems come up most often: inconsistent potency (the active compound per vial doesn't match the label), presence of synthesis impurities, and sterility failures.

Potency inconsistency is especially damaging for research reproducibility. If your supplier's vials average 80% of labeled potency and vary between batches, your concentration calculations are off in ways that are hard to trace back.

Why the Purity Number on a CoA Is Not Optional

Peptides are short chains of amino acids, assembled one unit at a time using a process called solid-phase peptide synthesis. Small errors in that assembly leave fragments and truncated chains behind. These impurities take up mass in the vial without being the compound you ordered.

The right tool for measuring purity is HPLC -- high-performance liquid chromatography. Think of it as a precise sorting machine. Your sample travels through a special column, and different molecules move through at different speeds. The machine records a peak for each component. The size of your compound's peak relative to everything else gives you the purity percentage.

A Certificate of Analysis (CoA) from a credible supplier will state the HPLC purity result. Anything below 98% deserves scrutiny. A CoA with no purity method listed, or one that just says "meets specifications," tells you almost nothing about what's actually in the vial.

Sourcing and Storage After the Panel Vote

The panel's support for access is meaningful -- it signals that the research value of these compounds is recognized at a regulatory level. Regulatory acknowledgment, though, does nothing to improve the purity of a specific vial from a specific supplier. That assessment starts with the CoA before you place an order.

A few sourcing checkpoints that matter:

• Third-party testing: CoAs from an independent lab carry more weight than those generated in-house by the manufacturer.
• Lot-specific documentation: Each production batch should have its own CoA with a lot number that matches what ships to you.
• Lyophilized form over solution: Lyophilized (freeze-dried) peptides survive shipping better and degrade more slowly than pre-dissolved stock.

Once the vial is in your lab, storage discipline protects the work you put into sourcing. Lyophilized peptides hold well at -20°C for months to a couple of years, depending on the compound. After reconstitution in bacteriostatic water (water preserved with 0.9% benzyl alcohol, which slows microbial growth), the usable window drops to a few weeks at 2-8°C. Each freeze-thaw cycle costs you a little purity, so aliquot before freezing rather than thawing the same vial repeatedly.

Label every reconstituted vial with the date and the concentration you calculated. That's the only way your reconstitution math stays verifiable across experiments -- and it's the first thing to check when a result looks off.

Frequently asked questions

What does FDA unapproved mean for research peptides?

It means the compound hasn't completed the clinical-trial drug-approval process for a specific medical use. Many are well-studied in research settings. Unapproved does not mean unknown or untested in labs.

What HPLC purity should a research-grade peptide have?

Look for 98% or higher on the Certificate of Analysis. Below that, a meaningful share of the vial's mass is impurities, which skews your concentration calculations and undermines reproducibility across experiments.

How long does a reconstituted peptide stay stable in the fridge?

Reconstituted in bacteriostatic water and kept at 2-8°C, most peptides remain usable for a few weeks. Lyophilized and stored at -20°C, stability extends to months or longer depending on the specific compound.

Prompted by this coverage at Google News →

Related from our lab: the pen · cartridges · bacteriostatic water · reconstitution calculators

Shared by PreppinPeppers for research, educational, and demonstration awareness only. We link to third-party coverage; we do not endorse it, and nothing here is medical advice or a recommendation to use any substance in humans or animals. Our products are sold for laboratory research use only.

What the research community gets wrong about verifying research peptide purity

• "Unapproved" is a regulatory status, not a purity grade. An FDA panel vote about access says nothing about what is inside one vial from one supplier. The purity of the material at your bench comes from how it was made and tested, so a named HPLC number on the lot's CoA tells you more than the approval label ever will.
• A high HPLC percentage is not the same as peptide content. HPLC purity compares the target peak to peptide-related impurities that absorb UV light, mostly deletion and truncated sequences from synthesis. It does not subtract salts, water, or counterions. A vial can read 98% pure and still carry a lot of non-peptide mass, so peptide content is a separate number worth asking for.
• An in-house CoA is not independent verification. A supplier can print a purity figure without any outside lab confirming it. A CoA that names a third-party testing lab, states the HPLC method, and carries a lot number that matches your vial label is stronger evidence than a bigger percentage on an unnamed sheet.
• Purity is not fixed once the vial reaches you. Rough handling degrades good material. Air and liquid interfaces from hard shaking, foaming, and repeated freeze-thaw can drive aggregation, while gentle mixing and rolling do not. Vortexing at full speed is not "just mixing."
• Lyophilized does not mean stable forever. Freeze-dried peptide held at low temperature lasts months to a couple of years depending on the compound, but once reconstituted the usable window in the fridge drops to weeks. Aliquoting before you freeze protects the material better than thawing the same vial again and again.

From our bench: Have you ever run the same lot on your own HPLC, or sent it to an independent lab, and compared the result to the number printed on the supplier's CoA? Tell us how your measured purity lined up with the stated figure, whether the lot number on the certificate matched your vial label, and which method the CoA named. Send us the side-by-side and we will add real reader measurements here.

Sources

1. Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
2. Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
3. Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
4. GenScript, Peptide Purity and HPLC Analysis (technical guidance)